Cepheid Announces European Approval Of Xpert MRSA Next Generation (NxG) Screening Test

The Number One, On-Demand Molecular Test for MRSA Colonization is Now Improved

SUNNYVALE, Calif., March 29, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced commercial availability, outside the United States, of Xpert® MRSA NxG, a next generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA). Xpert MRSA NxG has been updated to identify mecA- and mecCcontaining MRSA strains and detect new and emerging SCCmec subtypes with enhanced performance. The assay has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. Xpert MRSA NxG is an important update to the menu of 23 tests available internationally to run on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 10,000 systems deployed globally in both developed and emerging market countries.